Tarsus Pharmaceuticals, Inc.
TARS
$69.20
$0.320.47%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 606.33M | 535.08M | 451.36M | 366.10M | 295.52M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 606.33M | 535.08M | 451.36M | 366.10M | 295.52M |
| Cost of Revenue | 97.42M | 91.54M | 79.41M | 72.25M | 63.03M |
| Gross Profit | 508.92M | 443.54M | 371.95M | 293.85M | 232.50M |
| SG&A Expenses | 526.44M | 478.76M | 427.32M | 365.67M | 314.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 654.87M | 585.89M | 522.33M | 453.51M | 393.57M |
| Operating Income | -48.54M | -50.81M | -70.97M | -87.41M | -98.05M |
| Income Before Tax | -39.35M | -43.85M | -64.36M | -81.16M | -91.99M |
| Income Tax Expenses | 7.13M | 4.41M | 2.06M | -- | -- |
| Earnings from Continuing Operations | -46.48 | -48.27 | -66.42 | -81.16 | -91.99 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.48M | -48.27M | -66.42M | -81.16M | -91.99M |
| EBIT | -48.54M | -50.81M | -70.97M | -87.41M | -98.05M |
| EBITDA | -46.20M | -49.02M | -69.15M | -85.61M | -96.42M |
| EPS Basic | -1.08 | -1.13 | -1.61 | -2.01 | -2.33 |
| Normalized Basic EPS | -0.56 | -0.59 | -0.93 | -1.23 | -1.42 |
| EPS Diluted | -1.08 | -1.13 | -1.61 | -2.01 | -2.33 |
| Normalized Diluted EPS | -0.56 | -0.59 | -0.93 | -1.23 | -1.42 |
| Average Basic Shares Outstanding | 171.74M | 170.71M | 167.10M | 162.87M | 158.65M |
| Average Diluted Shares Outstanding | 171.74M | 170.71M | 167.10M | 162.87M | 158.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |